Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs Clopidogrel for Prevention of Restenosis in CLI (RIVAL-PAD)
NCT02260622Phase 2Completed
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Oct 2014
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rivaroxaban in critical limb ischemia (CLI), sponsored by Ottawa Hospital Research Institute. Started Oct 2014; status: completed.
02
Drugs
rivaroxaban
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT02260622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02260622.